RE: RE: RE: Disapointing attitude on board...my poiint is that sct had an oppounity on receipt of fda minutes to clarifty ii/iii, pivital vs 3, show me the efficacy, or whatever, so shareholders arenn't stumbling around guessing and at the same time, sct could have explained what they meant by "positive" in their dec release. seemed like an obvious move to me. micr1 should not have to phone and ask questions. (thanks for sharing your conversations though)....that kind of stuff should have been in an nr. instead...we get the mushroom treatment.... and the market continues to react as you'd expect.